Celyad SA (BR:CYAD) — Market Cap & Net Worth
Market Cap & Net Worth: Celyad SA (CYAD)
Celyad SA (BR:CYAD) has a market capitalization of $8.95 Million (€7.66 Million) as of June 19, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #27337 globally and #107 in its home market, demonstrating a -5.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celyad SA's stock price €0.27 by its total outstanding shares 44761905 (44.76 Million). Review Celyad SA total liabilities to assess the company's total debt and financial obligations.
Celyad SA Market Cap History: 2015 to 2026
Celyad SA's market capitalization history from 2015 to 2026. Data shows change from $2.53 Billion to $13.97 Million (-36.24% CAGR).
Index Memberships
Celyad SA is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$854.14 Billion | 0.00% | #104 of 108 |
|
CAC Health Care
FRHC
|
$257.52 Billion | 0.00% | #32 of 36 |
Weight: Celyad SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celyad SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celyad SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
200.32x
Celyad SA's market cap is 200.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.53 Billion | $3.00K | -$29.11 Million | 844279.45x | N/A |
| 2016 | $932.02 Million | $10.01 Million | -$23.61 Million | 93.09x | N/A |
| 2017 | $1.81 Billion | $3.54 Million | -$56.40 Million | 511.64x | N/A |
| 2018 | $868.18 Million | $3.12 Million | -$37.43 Million | 278.71x | N/A |
| 2019 | $507.61 Million | $6.00K | -$28.63 Million | 84602.38x | N/A |
| 2020 | $346.43 Million | $5.00K | -$17.20 Million | 69286.74x | N/A |
| 2023 | $20.41 Million | $102.00K | -$8.45 Million | 200.09x | N/A |
| 2024 | $37.26 Million | $186.00K | -$5.82 Million | 200.32x | N/A |
Competitor Companies of CYAD by Market Capitalization
Companies near Celyad SA in the global market cap rankings as of June 19, 2026.
Key companies related to Celyad SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Celyad SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Celyad SA's market cap moved from $2.53 Billion to $ 13.97 Million, with a yearly change of -36.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.97 Million | +57.06% |
| 2025 | €8.90 Million | -76.12% |
| 2024 | €37.26 Million | +82.56% |
| 2023 | €20.41 Million | -22.92% |
| 2022 | €26.48 Million | -85.60% |
| 2021 | €183.94 Million | -46.90% |
| 2020 | €346.43 Million | -31.75% |
| 2019 | €507.61 Million | -41.53% |
| 2018 | €868.18 Million | -52.07% |
| 2017 | €1.81 Billion | +94.33% |
| 2016 | €932.02 Million | -63.20% |
| 2015 | €2.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Celyad SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.95 Million USD |
| MoneyControl | $8.95 Million USD |
| MarketWatch | $8.95 Million USD |
| marketcap.company | $8.95 Million USD |
| Reuters | $8.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more